CoChat

Spotlight on liver macrophages for halting injury and progression in nonalcoholic fatty liver disease

The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.

Abstract

INTRODUCTION: Nonalcoholic fatty liver disease (NAFLD) is considered the hepatic manifestation of the metabolic syndrome and is rapidly emerging as the leading cause of liver-related morbidity and mortality. Macrophages play an essential role in the development and progression of NAFLD. AREAS COVERED: In this review, we provide an update on recent studies of drugs, which directly or indirectly affect macrophages in NAFLD, and discuss the implication of macrophage biomarkers to monitor the disease stage and progression/regression. EXPERT OPINION: There is an unmet need for a better understanding of disease pathogenesis from hepatic fat accumulation to disease progression with inflammation and fibrosis. We expect that future research will uncover additional objects/pathways as treatment targets. We speculate that this will involve better characterization of the gut microbiome, damage-associated molecular patterns (DAMPS) or molecules and pathways involved in the development of DAMPS, and advanced molecular biology studies including single-cell sequencing of macrophage subpopulations. In addition, we speculate that studies focusing on pharmaceuticals that improve insulin resistance, diminish the metabolic syndrome, and reduce fibrosis will prevail.

Overview

Integrity signals

Registry

Crossref · 10.1080/14728222.2022.2132145

Cites

74 of 74 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 74 references

Research works printed but not linked: 3

  1. Chen L, 2012, Hepato-gastroenterology, 59, 1208
  2. Ho MK, 1982, Journal of Immunology (Baltimore, MD: 1950), 128, 2281
  3. Bird TG, 2013, Science, 110, 6542

Cited by

See all 12

Metadata

Authors
Laursen, T. L., Mellemkjær, A., Møller, H. J., Grønbæk, H., & Kazankov, K.
Affiliations
  • Regional Hospital Randers (DK)
  • Aarhus University Hospital (DK)
Corresponding author
Grønbæk, Henning
Venue
Expert Opinion on Therapeutic Targets
Published
2022-08-03
Volume
26
Issue
8
Pages
697-705
ISSN
  • 1472-8222 (ISSN-L)
  • 1744-7631
OpenAlex
W4303198237
Cited by
12
References
74
Citations by year
2026: 2 · 2025: 2 · 2024: 4 · 2023: 4
FWCI
0.40
Type
journal article
Language
en
Open access
closed
Locations
  • Expert Opinion on Therapeutic Targets (publishedVersion)
  • PubMed (publishedVersion)
Funders
Steno Diabetes Center Aarhus
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
Keywords
non-alcoholic fatty liver disease, hepatic macrophages, liver fibrosis, liver inflammation, metabolic syndrome, insulin resistance, gut microbiota, damage-associated molecular patterns, macrophage heterogeneity, single-cell sequencing
MeSH terms
Pharmaceutical Preparations, Fibrosis, Humans, Liver, Macrophages, Disease Progression, Metabolic Syndrome, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Spotlight on liver macrophages for halting injury and progression in nonalcoholic fatty liver disease. https://app.cochat.ai/papers/10.1080/14728222.2022.2132145
The paper
Laursen, T. L., Mellemkjær, A., Møller, H. J., Grønbæk, H., & Kazankov, K. (2022). Spotlight on liver macrophages for halting injury and progression in nonalcoholic fatty liver disease. Expert Opinion on Therapeutic Targets. https://doi.org/10.1080/14728222.2022.2132145

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.